ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 732

Decreased Disease Activity and Corticosteroid Usage and Improved Quality of Life during Belimumab Treatment in Patients with Systemic Lupus Erythematosus – a Prospective Real-Life Observational Study

Ioannis Parodis1, Christopher Sjöwall2, Andreas Jönsen3, Agneta Zickert1, Martina Frodlund2, Daniel Ramsköld1, Anders A. Bengtsson3 and Iva Gunnarsson1, 1Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 2Rheumatology/AIR, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, 3Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: belimumab, Biologics, clinical practice and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Session Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Belimumab is the first biologic drug approved to treat Systemic Lupus Erythematosus (SLE). The efficacy of belimumab has been demonstrated through 2 phase III clinical trials. Real-life experiences are anticipated in order to form an opinion of how belimumab is used in clinical praxis and provide guidance for improvements in its future use. We investigated the clinical effects of belimumab in patients with active SLE despite standard of care therapy.

Methods: Fifty-two patients from Karolinska (n=25), Skåne (n=19), and Linköping (n=8) University Hospitals treated with belimumab were enrolled in this study and followed longitudinally. Global disease activity was assessed using the SLE Disease Activity Index 2000 (SLEDAI-2K), Systemic Lupus Activity Measure-Revised (SLAM-R), and a 100 mm Visual Analogue Scale (VAS) for Physician’s Global Assessment (PGA). Organ damage was evaluated according to the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Quality of Life (QoL) was evaluated by patients’ reports for pain, fatigue and well-being levels using 100 mm Visual Analogue Scales. Global health outcome was determined by the EuroQol Research Foundation 5 Dimension (EQ-5D) health questionnaire, scored according to the UK tariff. Functional status was assessed using the Stanford Health Assessment Questionnaire (HAQ) functional disability index.

Results: Belimumab was mainly given for musculoskeletal (n=24), mucocutaneous (n=24), hematological (n=10), renal (n=5), respiratory (n=4), and neurological (n=3) manifestations.

Significant decreases over time were observed for SLEDAI-2K (median baseline score: 7; range: 2–24; p<0.001), corresponding to a decrease of 3.42 over a year, SLAM-R (median baseline score: 13; range: 5–26; p<0.001) and PGA (p<0.001). We also observed decreases of prednisone equivalent dosages (mean baseline dose: 12.3 mg/day; range: 0–60 mg/day; p<0.001), corresponding to a decrease of 4.93 mg/day over a year. C4 levels increased significantly (p=0.006), but C3 levels remained unchanged. We observed significant improvements in well-being (p<0.001), pain (p<0.001) and fatigue (p=0.018), but no significant changes in HAQ and no significant improvements in EQ-5D. SDI scores remained stable.

Reasons for discontinuation included inadequate or uncertain effect (n=7), flare (n=5: increased proteinuria; arthritis, headache; rash, alopecia; biopsy-proven lupus nephritis WHO class III; CNS-lupus), adverse events (n=3: acute myeloid leukemia; ground glass opacity in computed tomography scan of the lungs, pulmonary arterial hypertension; insomnia, arrhythmia), allergic reactions (n=2) and pregnancy plans (n=2).

Conclusion: In this real-life observational study, belimumab treatment decreased disease activity, reduced corticosteroid usage and improved the patients’ quality of life in terms of pain, fatigue and well-being over time, but had no significant effects on their functional status. There was no progression of organ damage during the follow-up. The tolerability and safety profiles of belimumab in this study were comparable with those in previous reports from the phase III trials.


Disclosure: I. Parodis, None; C. Sjöwall, None; A. Jönsen, None; A. Zickert, None; M. Frodlund, None; D. Ramsköld, None; A. A. Bengtsson, None; I. Gunnarsson, None.

To cite this abstract in AMA style:

Parodis I, Sjöwall C, Jönsen A, Zickert A, Frodlund M, Ramsköld D, Bengtsson AA, Gunnarsson I. Decreased Disease Activity and Corticosteroid Usage and Improved Quality of Life during Belimumab Treatment in Patients with Systemic Lupus Erythematosus – a Prospective Real-Life Observational Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/decreased-disease-activity-and-corticosteroid-usage-and-improved-quality-of-life-during-belimumab-treatment-in-patients-with-systemic-lupus-erythematosus-ae-a-prospective-real-life-observatio/. Accessed May 26, 2022.
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/decreased-disease-activity-and-corticosteroid-usage-and-improved-quality-of-life-during-belimumab-treatment-in-patients-with-systemic-lupus-erythematosus-ae-a-prospective-real-life-observatio/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.